- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Mallinckrodt to distribute Myoview
Mallinckrodt has added another agent to its line of nuclear medicine imaging products. The vendor has signed a five-year agreement with Medi-Physics to distribute Myoview, a technetium-based cardiac imaging agent that provides physicians a view of
Mallinckrodt has added another agent to its line of nuclear medicine imaging products. The vendor has signed a five-year agreement with Medi-Physics to distribute Myoview, a technetium-based cardiac imaging agent that provides physicians a view of restricted blood supply to the heart muscle, according to the company.
Mallinckrodt of St. Louis and Medi-Physics of Arlington Heights, IL, will both provide the agent in the U.S. The agreement also includes a five-year extension.
In other Mallinckrodt news, the company has jointly announced with Molecular Biosystems that MBI's FS069 second-generation ultrasound contrast agent has been given the brand name Optison. Regulatory activity by the Food and Drug Administration on that agent has been temporarily halted following a U.S. District Court preliminary injunction on April 21 (SCAN 4/30/97).
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
AI Adjudication Bolsters Chest CT Assessment of Lung Adenocarcinoma
April 11th 2024The inclusion of simulated adjudication for resolving discordant nodule classifications in a deep learning model for assessing lung adenocarcinoma on chest CT resulted in a 12 percent increase in sensitivity rate.
